Topical Antiperspirant for Hand-Foot Syndrome

Topical Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Associated With Capecitabine

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00213993

Enrollment

Registered

2005-09-21

Start date

2005-05-31

Completion date

2007-01-31

Last updated

2015-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palmar-plantar Erythrodysesthesia

Brief summary

The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.

Interventions

DRUGantiperspirant

antiperspirant topically once daily to one foot

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Has not previously received a regimen that includes 5-fluorouracil * \> 18 years old * No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant

Exclusion criteria

* \< 18 years of age

Design outcomes

Primary

Measure	Time frame
reduction in palm and/or sole pain	after each of first four cycles of chemotherapy

Secondary

Measure	Time frame
evaluation of utility of digital photography in the following palmar-plantar erythrodysesthesia (PPES)	after each of first four cycles of chemotherapy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026